Reported Thursday, Roche's Genentech Halts SKYSCRAPER-06 Trial After Tiragolumab Plus Tecentriq And Chemotherapy Show Reduced Efficacy Compared To Comparator Arm
Reported Thursday, Roche's Genentech Halts SKYSCRAPER-06 Trial After Tiragolumab Plus Tecentriq And Chemotherapy Show Reduced Efficacy Compared To Comparator Arm
罗氏的亨特西公司周四报告称，在提拉戈卢玛胶囊、特喜宁以及化疗联合治疗方案的 SKYSCRAPER-06 试验中，疗效相较于对照组有所降低而中止了试验。
- SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim analysis –
- The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy compared to the comparator arm –
- Safety was consistent with previous studies, however we intend to halt the trial due to reduced efficacy compared to the comparator arm –
- SKYSCRAPER-06评估tiragolumab加Tecentriq和化疗在主要分析中未达到无进展生存期和在第一次中期分析中的总生存期主要终点—
- 与对照组相比，tiragolumab加Tecentriq和化疗的联合治疗效果较差—
- 虽然安全性与以往研究一致，但由于效果不及对照组，我们打算停止该试验—